×
About 7,600 results

ALLMedicine™ Somatostatin Center

Research & Reviews  2,743 results

Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associa...
https://doi.org/10.1016/j.clinthera.2021.10.014
Clinical Therapeutics; Duck L, Demolin G et. al.

Dec 1st, 2021 - Inoperable malignant intestinal obstruction (IMIO) is a severe complication in patients with cancer, usually gastrointestinal or gynecologic in origin. For patients with IMIO, there is a need to relieve symptoms and limit nasogastric tube (NGT) us...

Lack of hyper-inhibition of oriens-lacunosum moleculare cells by vasoactive intestinal ...
https://doi.org/10.1523/ENEURO.0299-21.2021
ENeuro Wyeth M, Buckmaster PS

Nov 26th, 2021 - Temporal lobe epilepsy remains a common disorder with no cure and inadequate treatments, potentially due to an incomplete understanding of how seizures start. CA1 pyramidal cells and many inhibitory interneurons increase their firing rate in the s...

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-an...
https://doi.org/10.1002/14651858.CD013700.pub2
The Cochrane Database of Systematic Reviews; Walter MA, Nesti C et. al.

Nov 26th, 2021 - Several available therapies for neuroendocrine tumours (NETs) have demonstrated efficacy in randomised controlled trials. However, translation of these results into improved care faces several challenges, as a direct comparison of the most pertine...

Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome
https://clinicaltrials.gov/ct2/show/NCT02019706

Nov 25th, 2021 - Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral sour...

Biology and Treatment of Meningiomas: A Reappraisal.
https://doi.org/10.1016/j.hoc.2021.09.003
Hematology/oncology Clinics of North America; McFaline-Figueroa JR, Kaley TJ et. al.

Nov 22nd, 2021 - Meningiomas are largely indolent tumors with a benign clinical course, but a minority exhibit aggressive behavior characterized by rapid growth, neurologic deficits, and increased mortality. Identifying high-risk patients requiring intervention is...

see more →

Guidelines  7 results

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expe...
https://doi.org/10.1093/annonc/mdv041
Annals of Oncology : Official Journal of the European Soc... Caplin ME, Baudin E et. al.

Feb 4th, 2015 - Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management. Bibliographical ...

Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (...
https://doi.org/10.1055/s-0034-1377875
Endoscopy Dumonceau JM, Andriulli A et. al.

Aug 26th, 2014 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Main recommendations 1 ESGE recomme...

Expert consensus document: A consensus on the medical treatment of acromegaly.
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide the...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622744
European Journal of Nuclear Medicine and Molecular Imaging; Bodei L, Mueller-Brand J et. al.

Feb 8th, 2013 - Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabelled peptide designed to target with high affinity and specificity receptors overexpressed on tumours. PR...

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neur...
https://doi.org/10.1007/s12094-011-0695-9
Clinical & Translational Oncology : Official Publication ... García-Carbonero R, Salazar R et. al.

Aug 9th, 2011 - Gastroenteropancreatic neuroendocrine tumours (GEP NETs) represent a heterogenous family of tumours with growing incidence and challenging clinical management. Unlike other solid tumours, they have the ability to secrete different peptides and neu...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  118 results

Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome
https://clinicaltrials.gov/ct2/show/NCT02019706

Nov 25th, 2021 - Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral sour...

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04927416

Oct 28th, 2021 - The study is designed to identify the patients with metastatic radioactive iodine (RAI) non-avid or non-responsive thyroid cancer RAI non-responsive Hurthle cell thyroid cancer (HTC), differentiated thyroid cancer (DTC) and metastatic medullary th...

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
https://clinicaltrials.gov/ct2/show/NCT03972488

Oct 22nd, 2021 - The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose...

Neuroendocrine Tumors - Patient Reported Outcomes
https://clinicaltrials.gov/ct2/show/NCT05064150

Oct 11th, 2021 - Neuroendocrine tumors (NETs) are a group of neoplasms that occur most frequently in the gastrointestinal tract, pancreas and the lungs collectively referred to as gastroenteropancreatic (GEP-NETs) and lung-NETs. There are currently fewer than 180,...

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
https://clinicaltrials.gov/ct2/show/NCT04379817

Oct 8th, 2021 - This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the f...

see more →

News  151 results

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs
https://www.onclive.com/view/dr-reidy-lagunes-on-the-results-of-the-spinet-study-by-tumor-subtype-in-bp-nets

Nov 17th, 2021 - Diane Reidy-Lagunes, MD, medical oncologist, associate deputy physician in chief, Regional Care Network, physician ambassador, Patient Family Advisory Council for Quality, president, MSK Medical Staff, Memorial Sloan Kettering Cancer Center, discu...

Dr. Halperin on the Efficacy of the Protocol PEN-221-001 Study in Advanced GI NETs
https://www.onclive.com/view/dr-halperin-on-the-efficacy-of-the-protocol-pen-221-001-study-in-advanced-gi-nets

Nov 16th, 2021 - Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety results of the phase 1/2a Protocol...

Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors
https://www.onclive.com/view/tidutamab-shows-early-tolerability-active-immune-profile-in-advanced-neuroendocrine-tumors

Nov 15th, 2021 - Tidutamab (previously XmAb18087) was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors (NETs) of pancreatic, gastrointestinal (GI), lung and undetermined ...

New Class of Radiopharmaceutical Therapy Makes Headway in Prostate Cancer
https://www.onclive.com/view/new-class-of-radiopharmaceutical-therapy-makes-headway-in-prostate-cancer

Oct 21st, 2021 - Investigators have made great strides in the development of radiopharmaceuticals for prostate cancer diagnostics, culminating in recent FDA approvals for the first prostate-specific membrane antigen (PSMA)–targeted radioligands, gallium 68 (68Ga)–...

Liver-Directed Therapies Enhance Treatment Landscape for Metastatic NETs
https://www.onclive.com/view/liver-directed-therapies-enhance-treatment-landscape-for-metastatic-nets

Oct 6th, 2021 - Juan C. Camacho, MD Patients with neuroendocrine tumors (NETs) that have metastasized to the liver derive clinical benefit from locoregional therapies, but treatment guidelines for employing these strategies must be more fully developed, accordin...

see more →

Patient Education  2 results see all →